SciSparc: Funding, Investors & Team (Oct 2026)
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.
SciSparc has raised $10.0M across 1 funding round on record, the most recent a Post-IPO Equity of $10.0M announced in May 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SciSparc Company Profile and Key Stats
Latest funding round on record: May 2022.
SciSparc Funding Rounds
SciSparc Founders and Leadership Team
No contact details are on record for this team yet.
SciSparc Funding Compared to Other Biotechnology Startups
SciSparc's latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SciSparc in Biotechnology and Giv'atayim
Companies Similar to SciSparc
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
SciSparc Funding FAQs
What does SciSparc do?
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.
How much funding has SciSparc raised?
SciSparc has raised $10.0M across 1 round on record. The most recent is a Post-IPO Equity of $10.0M announced in May 2022.
When did SciSparc last raise funding?
SciSparc's most recent funding round on record is a Post-IPO Equity of $10.0M, announced in May 2022.
Who is the CEO of SciSparc?
Ari Aminetzah is listed as CEO at SciSparc.
Where is SciSparc headquartered?
SciSparc is based in Giv'atayim, Tel Aviv, Israel.
How many employees does SciSparc have?
SciSparc is in the 11-50 employee band.
How does SciSparc's funding compare to other Biotechnology startups?
SciSparc's latest round of $10.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's SciSparc Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SciSparc is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.